Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 5/20 | 0.43 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29440193 | 0.88 | CTSL (0.41) | HTR2CELANEFKBP1AMEN1KMT2A | |
| SCHEMBL29440106 | 0.77 | HTR2C (0.51) | HTR2CFKBP1AMITFMAPTHTT | |
| SCHEMBL29440077 | 0.77 | HTR2C (0.51) | HTR2CFKBP1AMITFMAPTHTT | |
| SCHEMBL26010045 | 0.76 | CPB1 (0.38) | HTR2CFKBP1AHTTMEN1KMT2A | |
| SCHEMBL26009422 | 0.75 | — | — | |
| SCHEMBL1012764 | 0.72 | HTR2C (0.52) | HTR2CFKBP1AMITFMAPTHTT | |
| SCHEMBL29152587 | 0.69 | ALDH1A1 (0.50) | MEN1KMT2ANPSR1GAANPC1 | |
| SCHEMBL28880336 | 0.68 | OPRL1 (0.49) | HTR2CFKBP1AMITFMAPTHTT | |
| SCHEMBL3419151 | 0.68 | OPRL1 (0.49) | HTR2CFKBP1AMITFMAPTHTT | |
| SCHEMBL16236781 | 0.67 | NR1H2 (0.49) | HTR2CMITFMAPTHTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4199925-B1 | CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12497362-B2 | Cyclopentapyrrole orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2025-12-16 | — | — | US | disclosed |
| US-20230257348-A1 | CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257348-A1 | CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-08-17 | — | — | US | disclosed |
| EP-4199925-A1 | CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-06-28 | — | — | EP | disclosed |
| WO-2022040058-A1 | CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12497362-B2 | Cyclopentapyrrole orexin receptor agonists | HCRTR2, HCRTR1, NPY1R | HTR2C 87/4885ELANE 4106/4885FKBP1A 158/4885 |
| US-20230257348-A1 | CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS | HCRTR2, HCRTR1, NPY1R | HTR2C 87/4885ELANE 4106/4885FKBP1A 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.